Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This is a phase II, exploratory, open-label, single arm study of BYL719 monotherapy, a
selective phosphatidylinositol 3-kinase (PI3K) alpha inhibitor, in adult patients with
advanced metastatic breast cancer progressing after first line therapy. Patients with
advanced hormone receptor positive tumors will be required to have an alteration of the PI3K
pathway. Those patients with advanced triple negative breast cancers are genetically
unselected for this study.